The securities fraud trial against pharmaceutical executive Martin Shkreli got off to a rough start for the so-called Pharma Bro on Monday after the judge in the case granted the prosecutors’ motion to preclude arguments that he did not intend to defraud investors.
Shkreli, who gained widespread opprobrium for increasing the price of a drug used mostly by HIV and AIDS patients from $13.50 per pill to $700, is accused of scheming to defraud investors in two hedge funds he founded and then scheming to misappropriate $11 million in assets from Retrophin Inc., the biopharmaceutical company he led, to pay off the investors.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
